A research study to look into how semaglutide, together with a lower dose of insulin glargine, compares to a higher dose of insulin glargine alone in people with type 2 diabetes (SUSTAIN OPTIMIZE)
- Conditions
- Participants with T2D and overweightTherapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]
- Registration Number
- CTIS2024-510612-75-00
- Lead Sponsor
- ovo Nordisk A/S
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 568
Diagnosed with T2D mellitus =180 days before screening., HbA1c of 7-10% (53-86 mmol/mol) (both inclusive) as assessed by central laboratory on the day of screening., Body mass index (BMI) =25 kg/m2 on the day of screening., Stable daily dose(s) =90 days before screening of any of the following anti-diabetic drugs or combination regimens: -Any metformin formulations =1500 mg or maximum tolerated or effective dose. -Any metformin combination formulation =1500 mg or maximum tolerated or effective dose. The treatment can be with or without SGLT-2 inhibitors., Treated with a once daily basal insulin (e.g. insulin glargine U100 or U300, NPH insulin, insulin detemir, insulin degludec) =40 U/day for =90 days before screening. Short-term bolus insulin treatment for a maximum of 14 days before screening is allowed.
Uncontrolled and potentially unstable diabetic retinopathy or maculopathy. Verified by a fundus examination performed within the past 90 days before screening or in the period between screening and randomisation. Pharmacological pupil-dilation is a requirement unless using a digital fundus photography camera specified for non-dilated examination., Potentially missed diagnosis of Type 1 diabetes (T1D) or latent autoimmune diabetes in adults (LADA) verified by C-peptide <0.26 nmol/L or 260 pmol/L (0.78 ng/mL) or antibodies to glutamic acid decarboxylase (anti-GAD) >5 units/mL, as measured by the central laboratory at screening., Presence or historya of pancreatitis (acute or chronic)., Renal impairment measured as estimated Glomerular Filtration Rate (eGFR) value of <30 mL/min/1.73 m2 at screening as defined by KDIGO 2012 classification., Any episodes of diabetic ketoacidosis within 90 days before screening., Known hypoglycaemic unawareness as indicated by the investigator according to Clarke’s questionnaire question 8.
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method